Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab plus induction chemotherapy followed by radical treatment in head and neck squamous cell carcinoma
ChiCTR2200064423Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zimberelimab in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and 2 more, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: objective response rate. Started Oct 2022; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2200064423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064423.